Elliott joined the firm in August 2019 and heads the Psychoactive Medicines Law & Regulatory team.
Elliott’s research into psychoactive plants and chemicals began in 2006, while studying for behavioural neuroscience exams at Kent University. Having studied psychoactive substances and mental health across a multitude of disciplines, qualifying as a regulatory solicitor, and subsequently specialising as one of the UK’s first medical cannabis lawyers, Elliott is uniquely placed to support the upcoming psychedelic medicines industry on its regulatory journey.
As part of the Cannabis Law team at Mackrell, Elliott advised some of the world’s leading cannabis companies, and worked with all corners of the industry, including regulators, trade bodies, academics, policy institutes and patients. Having previously acted for global investment banks, Elliott brings his experience of liaising with multi-national civil and criminal regulators in a variety of contexts, and advising on a broad range of EU and international regulations. Before joining the world of banking, Elliott worked on medical devices litigation at a magic circle law firm.
Elliott holds a Certificate in Medical Cannabis from the University of Colorado, completed an undergraduate degree in Philosophy and Psychology at the University of Kent, and holds a Diploma in Law and a Postgraduate Diploma in Legal Practice. He is recognised in the Global Law Experts directory in the Medical Cannabis category, the Spear’s 500 directory for commercial and regulatory cannabis practice and the Cannabis Law Report’s Global Top 200 Cannabis Lawyers directory.
Elliott is keenly interested in psychedelic medicine, drug policy reform and regulation, and is a long time supporting community member of the organisation DrugScience – the leading independent scientific body on drugs in the UK. Elliott is due to complete a qualification in Counselling and Psychotherapy towards the end of 2020 and is soon to complete the University of Geneva’s Drugs, Drug Policy and Health program.
He is part of the firm’s stated intent to be at the forefront of global legal developments in medicinal cannabis and other psychoactive substances.